Baxter International, Inc. Stockholders Should Contact Robbins LLP For Information About The Pending Leading Plaintiff Deadline in The BAX Class Action
SAN DIEGO, CA / ACCESS Newswire / December 5, 2025 / Company: Baxter International, Inc. (NYSE:BAX) is a global company that develops, manufactures, and markets medical products used in hospitals and other healthcare facilities.
What is the class period? February 23, 2022 and October 29, 2025
What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Baxter International, Inc. because the Company mislead investors regarding the safety of its Novum LVP.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What are the allegations? According to the complaint, during the class period, defendants assured investors that the Novum LVP "has some of the most advanced safety features that are available" and touted the device's "precision." Baxter executives also repeatedly boasted about the positive customer feedback, both in Canada and the United States, that the Company received on the Novum LVP, and assured investors that it had "address[ed] all of [the] issues" from its launch in Canada and that the United States launch.
Plaintiff alleges that in truth, the Novum LVP lacked precision and was not well received by customers. To the contrary, the device was susceptible to chronic under-infusion and over-infusion, putting patients at risk. Further, unknown to investors, during the class period, Baxter received at least 79 customer reports of serious injury and two reports of deaths related to the Novum LVP.
Plaintiff further alleges that on July 31, 2025, Baxter announced it would "voluntarily and temporarily pause shipments and planned installations of the Novum LVP." On this news, Baxter stock dropped 22.4%, closing at $21.76 on July 31, 2025. Then, on October 29, 2025, Baxter revealed that its third quarter top line revenue came in lower than its previously issued guidance, in part, due to lower infusion pump sales because of the shipment and installation hold of the Novum LVP. In addition, the Company announced that it intends to reduce the quarterly dividend to $0.01 per share, from its previous $0.17 per share, beginning with the dividend to be paid in January 2026. As a result of these disclosures, Baxter's stock price declined by an additional $3.26 per share, or 14.5%.
What are the next steps? You may be eligible to participate in the class action against Baxter International, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by December 15, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Baxter International, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
[email protected]
(800) 350-6003
www.robbinsllp.com
SOURCE: Robbins LLP